IMNN
Imunon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.83
+0.35%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +9.3%
- EBIT
- +7.4%
- EPS
- +66.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +104.2%
- EPS
- +10.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- +22.9%
- EBIT
- +23.4%
- Net income
- +22.2%
- EPS
- +67.6%
- Free cash flow
- +24.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026